Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Neuroendocrine 2Blast Crisis 2Thymoma 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Ovarian Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5Specimen Handling 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 3cabozantinib 2X-Rays 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sunitinib 1Sorafenib 1Salts 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Everolimus 1Etoposide 1Disulfides 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroendocrine Tumors × belinostat × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡